These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
823 related articles for article (PubMed ID: 2529429)
21. [Histological diagnosis of Ph-negative myeloproliferative neoplasia. An overview]. Campr V Cesk Patol; 2011 Jul; 47(3):84-93. PubMed ID: 21887923 [TBL] [Abstract][Full Text] [Related]
22. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia. Michiels JJ Hematol J; 2004; 5(2):93-102. PubMed ID: 15048058 [TBL] [Abstract][Full Text] [Related]
23. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Michiels JJ; Thiele J Int J Hematol; 2002 Aug; 76(2):133-45. PubMed ID: 12215011 [TBL] [Abstract][Full Text] [Related]
24. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation]. Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211 [TBL] [Abstract][Full Text] [Related]
26. [Use of interferon in the treatment of chronic myeloproliferative disorders]. Robak T Acta Haematol Pol; 1992; 23(2 Suppl 1):30-7. PubMed ID: 1488870 [TBL] [Abstract][Full Text] [Related]
27. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome]. Brière J Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652 [TBL] [Abstract][Full Text] [Related]
28. Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification. Buhr T; Georgii A; Choritz H Pathol Res Pract; 1993 Mar; 189(2):121-32. PubMed ID: 8321741 [TBL] [Abstract][Full Text] [Related]
29. [Unusual case of chronic myeloproliferative syndrome]. Tosato F; Fossaluzza V Arch Sci Med (Torino); 1982; 139(4):531-5. PubMed ID: 6891999 [TBL] [Abstract][Full Text] [Related]
30. Myeloproliferative disorders. Classification and diagnostic features with special emphasis on chronic myelogenous leukemia and agnogenic myeloid metaplasia. Hyun BH; Gulati GL; Ashton JK Clin Lab Med; 1990 Dec; 10(4):825-38. PubMed ID: 2272176 [TBL] [Abstract][Full Text] [Related]
31. Patho-anatomical features of the bone marrow. Lennert K; Nagai K; Schwarze EW Clin Haematol; 1975 Jun; 4(2):331-51. PubMed ID: 1102191 [No Abstract] [Full Text] [Related]
33. [Chronic myeloproliferative disorders. The new WHO classification]. Thiele J; Kvasnicka HM Pathologe; 2001 Nov; 22(6):429-43. PubMed ID: 11766643 [TBL] [Abstract][Full Text] [Related]
34. Is it chronic idiopathic myelofibrosis, myelofibrosis with myeloid metaplasia, chronic megakaryocytic-granulocytic myelosis, or chronic megakaryocytic leukemia? Further thoughts on the nosology of the clonal myeloid disorders. Lichtman MA Leukemia; 2005 Jul; 19(7):1139-41. PubMed ID: 15902283 [No Abstract] [Full Text] [Related]
35. Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression. Panteli K; Zagorianakou N; Bai M; Katsaraki A; Agnantis NJ; Bourantas K Eur J Haematol; 2004 Jun; 72(6):410-5. PubMed ID: 15128419 [TBL] [Abstract][Full Text] [Related]
37. Bone marrow histopathology in myeloproliferative disorders--current diagnostic approach. Thiele J; Kvasnicka HM; Orazi A Semin Hematol; 2005 Oct; 42(4):184-95. PubMed ID: 16210032 [TBL] [Abstract][Full Text] [Related]
38. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera. Abdulkarim K; Ridell B; Johansson P; Kutti J; Safai-Kutti S; Andréasson B Eur J Haematol; 2011 Feb; 86(2):148-55. PubMed ID: 21059102 [TBL] [Abstract][Full Text] [Related]